Register
Adjunct dapagliflozin treatment improves glycemic control in patients with type 1 diabetes |
Journal Updates
eMediNexus Coverage from: 
Adjunct dapagliflozin treatment improves glycemic control in patients with type 1 diabetes
eMediNexus,  04 July 2018
remove_red_eye 649 Views
#Diabetes and Endocrinology #Internal Medicine #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

Addition of dapagliflozin to intensive insulin therapy in adults with type 1 diabetes who had suboptimal glycemic control reduced blood glucose, aided in weight loss and led to a reduction in insulin doses. However, it also slightly increased the risk of diabetic ketoacidosis risk. These findings from the DEPICT-2 Study were presented June 24, 2018 at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!